Tohru Kobayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tohru Kobayashi has a total of 319 co-authors. Here are the top co-authors by number of shared publications:
Tomio Kobayashi
Division of Cardiology, Gunma Children's Medical Center, Shibukawa, Gunma, Japan
5 shared publicationsAkihiro Morikawa
4 shared publications- Kiwako Yamamoto-Hanada
Allergy Center, National Center for Child Health and Development, Tokyo, Japan
4 shared publications - Shintaro Iwamoto
Biostatistics Unit, Department of Data Science, National Center for Child Health and Development, Tokyo, Japan
4 shared publications - Yukihiro Ohya
Department of Occupational and Environmental Health Nagoya City University Nagoya Japan
4 shared publications - Ayako Arai
Department of Hematology and Biophysical Systems Analysis, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan
3 shared publications
Latest Publications
Three‐Year Follow‐Up of the PACI Randomized Controlled Trial (PACI‐ON): Effects of Early Intervention for Atopic Dermatitis on Atopic March
Background: The Prevention of Allergy via Cutaneous Intervention (PACI) randomized controlled trial (RCT) demonstrated that early enhanced topical corticosteroid (TCS) therapy modestly reduced food allergy (FA) at 28 weeks of age. The present prospective follow‐up study (PACI‐ON) evaluated whether these effects persisted to age 3 years. Methods: Participants were randomized in infancy to early enhanced (proactive) or early conventional (reactive) TCS treatment (1:1) for atopic dermatitis (AD) until 28 weeks. A total of 590 (91%) children who completed the PACI RCT were followed to age 3 years. During follow‐up, no protocolized interventions were given; all participants received usual care. Main outcomes included physician‐diagnosed FA, AD severity (EASI, POEM), sensitization profiles, allergic comorbidities, and growth parameters as safety outcomes. Results: At age 3 years, the prevalence of any FA remained lower in the early enhanced group than in the conventional group (47.4% vs. 58.8%, p = 0.006), mainly driven by a reduced prevalence of raw egg allergy (30.4% vs. 40.5%, p = 0.013). No between‐group differences were observed for wheeze, asthma, or rhinitis. Japanese cedar sensitization at age 2 was lower in the enhanced group (6.1% vs. 12.2%, p = 0.02 6) but not at age 3. AD control and quality of life were well maintained and similar across groups, with > 90% achieving mild or less disease. Early growth suppression at 1 year resolved by age 3. Conclusion: Early enhanced AD intervention was associated with a sustained modest reduction in its planned primary follow‐up outcome of FA and safety (growth) up to age 3. Although most differences were small and may reflect early diagnosis and good overall management in both groups, the findings support early AD treatment as a potential strategy to modify allergic disease trajectories.
Three‐Year Follow‐Up of the PACI Randomized Controlled Trial (PACI‐ON): Effects of Early Intervention for Atopic Dermatitis on Atopic March
Background: The Prevention of Allergy via Cutaneous Intervention (PACI) randomized controlled trial (RCT) demonstrated that early enhanced topical corticosteroid (TCS) therapy modestly reduced food allergy (FA) at 28 weeks of age. The present prospective follow‐up study (PACI‐ON) evaluated whether these effects persisted to age 3 years. Methods: Participants were randomized in infancy to early enhanced (proactive) or early conventional (reactive) TCS treatment (1:1) for atopic dermatitis (AD) until 28 weeks. A total of 590 (91%) children who completed the PACI RCT were followed to age 3 years. During follow‐up, no protocolized interventions were given; all participants received usual care. Main outcomes included physician‐diagnosed FA, AD severity (EASI, POEM), sensitization profiles, allergic comorbidities, and growth parameters as safety outcomes. Results: At age 3 years, the prevalence of any FA remained lower in the early enhanced group than in the conventional group (47.4% vs. 58.8%, p = 0.006), mainly driven by a reduced prevalence of raw egg allergy (30.4% vs. 40.5%, p = 0.013). No between‐group differences were observed for wheeze, asthma, or rhinitis. Japanese cedar sensitization at age 2 was lower in the enhanced group (6.1% vs. 12.2%, p = 0.02 6) but not at age 3. AD control and quality of life were well maintained and similar across groups, with > 90% achieving mild or less disease. Early growth suppression at 1 year resolved by age 3. Conclusion: Early enhanced AD intervention was associated with a sustained modest reduction in its planned primary follow‐up outcome of FA and safety (growth) up to age 3. Although most differences were small and may reflect early diagnosis and good overall management in both groups, the findings support early AD treatment as a potential strategy to modify allergic disease trajectories.
- Open Access
Predicting coronary artery abnormalities in Kawasaki disease: Model development and external validation
Background Kawasaki disease (KD) is an acute, pediatric vasculitis associated with coronary artery abnormality (CAA) development. Echocardiography at month 1 post-diagnosis remains the standard for CAA surveillance despite limitations, including patient distress and increased healthcare burden. With declining CAA incidence due to improved treatment, the need for routine follow-up imaging is being reconsidered. This study aimed to develop and externally validate models for predicting CAA development and guide the need for echocardiography. Methods This study used two prospective multicenter Japanese registries: PEACOCK for model development and internal validation, and Post-RAISE for external validation. The primary outcome was CAA at the month 1 follow-up, defined as a maximum coronary artery Z score (Zmax) ≥ 2. Twenty-nine clinical, laboratory, echocardiographic, and treatment-related variables obtained within one week of diagnosis were selected as predictors. The models included simple models using the previous Zmax as a single predictor, logistic regression models, and machine learning models (LightGBM and XGBoost). Their discrimination, calibration, and clinical utility were assessed. Results After excluding patients without outcome data, 4,973 and 2,438 patients from PEACOCK and Post-RAISE, respectively, were included. The CAA incidence at month 1 was 5.5% and 6.8% for the respective group. For external validation, a simple model using the Zmax at week 1 produced an area under the curve of 0.79, which failed to improve by more than 0.02 after other variables were added or more complex models were used. Even the best-performing models with a highly sensitive threshold failed to reduce the need for echocardiography at month 1 by more than 30% while maintaining the number of undiagnosed CAA cases to less than ten. The predictive performance declined considerably when the Zmax was omitted from the multivariable models. Conclusions The Zmax at week 1 was the strongest predictor of CAA at month 1 post-diagnosis. Even advanced models incorporating additional variables failed to achieve a clinically acceptable trade-off between reducing the need for echocardiography and reducing the number of undiagnosed CAA cases. Until superior predictors are identified, echocardiography at month 1 should remain the standard practice. What Is New? The maximum Z score on echocardiography one week after diagnosis was the strongest of 29 variables for predicting coronary artery abnormalities (CAA) in patients with Kawasaki disease. Even the most sensitive models had a suboptimal ability to predict CAA development and reduce the need for imaging studies, suggesting they have limited utility in clinical decision-making. What Are the Clinical Implications? Until more accurate predictors are found or imaging strategies are optimized, performing echocardiography at one-month follow-up should remain the standard of care.
Open AccessPredicting coronary artery abnormalities in Kawasaki disease: Model development and external validation
Background Kawasaki disease (KD) is an acute, pediatric vasculitis associated with coronary artery abnormality (CAA) development. Echocardiography at month 1 post-diagnosis remains the standard for CAA surveillance despite limitations, including patient distress and increased healthcare burden. With declining CAA incidence due to improved treatment, the need for routine follow-up imaging is being reconsidered. This study aimed to develop and externally validate models for predicting CAA development and guide the need for echocardiography. Methods This study used two prospective multicenter Japanese registries: PEACOCK for model development and internal validation, and Post-RAISE for external validation. The primary outcome was CAA at the month 1 follow-up, defined as a maximum coronary artery Z score (Zmax) ≥ 2. Twenty-nine clinical, laboratory, echocardiographic, and treatment-related variables obtained within one week of diagnosis were selected as predictors. The models included simple models using the previous Zmax as a single predictor, logistic regression models, and machine learning models (LightGBM and XGBoost). Their discrimination, calibration, and clinical utility were assessed. Results After excluding patients without outcome data, 4,973 and 2,438 patients from PEACOCK and Post-RAISE, respectively, were included. The CAA incidence at month 1 was 5.5% and 6.8% for the respective group. For external validation, a simple model using the Zmax at week 1 produced an area under the curve of 0.79, which failed to improve by more than 0.02 after other variables were added or more complex models were used. Even the best-performing models with a highly sensitive threshold failed to reduce the need for echocardiography at month 1 by more than 30% while maintaining the number of undiagnosed CAA cases to less than ten. The predictive performance declined considerably when the Zmax was omitted from the multivariable models. Conclusions The Zmax at week 1 was the strongest predictor of CAA at month 1 post-diagnosis. Even advanced models incorporating additional variables failed to achieve a clinically acceptable trade-off between reducing the need for echocardiography and reducing the number of undiagnosed CAA cases. Until superior predictors are identified, echocardiography at month 1 should remain the standard practice. What Is New? The maximum Z score on echocardiography one week after diagnosis was the strongest of 29 variables for predicting coronary artery abnormalities (CAA) in patients with Kawasaki disease. Even the most sensitive models had a suboptimal ability to predict CAA development and reduce the need for imaging studies, suggesting they have limited utility in clinical decision-making. What Are the Clinical Implications? Until more accurate predictors are found or imaging strategies are optimized, performing echocardiography at one-month follow-up should remain the standard of care.
- Open Access
- 26 March 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (7) , 580-582
DIFENSE Study Protocol: Early Intervention With Difamilast Ointment in Infantile Early‐Onset Atopic Dermatitis for Prevention of Transcutaneous Sensitisation
- 26 March 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (7) , 580-582
Open AccessDIFENSE Study Protocol: Early Intervention With Difamilast Ointment in Infantile Early‐Onset Atopic Dermatitis for Prevention of Transcutaneous Sensitisation
- Open Access
- 9 September 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e59928
Prevention of Recurrent Spontaneous Preterm Delivery Using Probiotics (Clostridium butyricum, Enterococcus faecium, and Bacillus subtilis; PPP Trial): Protocol for a Prospective, Single-Arm, Nonblinded, Multicenter Trial
Background: The rate of recurrent spontaneous preterm delivery (sPTD) ranges between 27% and 34% and is 22.3% in Japan. Although it currently remains unclear whether probiotics prevent sPTD, retrospective studies recently reported a reduction in the rate of recurrent sPTD with the administration of probiotics including Clostridium spp., which induce regulatory T cells that play an important role in maintaining pregnancy. Objective: The objective of this trial is to evaluate the preventative effects of available oral probiotics, including Clostridium butyricum, on recurrent sPTD. Methods: This is a prospective, single-arm, nonblinded, multicenter trial in Japan. The sample size required for this trial is 345 pregnant women with a history of sPTD, considering a clinically significant reduction in the relative risk of 30% (risk ratio=0.7). The primary endpoint is the rate of recurrent sPTD at <37 weeks of gestation. The secondary endpoints are the rate of sPTD at <34 weeks of gestation, the rate of recurrent sPTD at <28 weeks of gestation, the ratio of intestinal Clostridium spp. (detected by next-generation sequencing), and bacterial vaginosis (using the Nugent score). Results: The trial procedures were approved by the Clinical Research Review Board of Toyama University Hospital (SCR2020008) on March 31, 2021. The trial was registered on the Japan Registry of Clinical Trial website on April 28, 2021. Recruitment began on May 1, 2021, and the trial is estimated to finish on March 31, 2025. Conclusions: The findings will clarify the rate of recurrent sPTD following probiotic administration including Clostridium butyricum. Outcomes from this trial will inform clinical practice and guide future randomized controlled trials. Trial Registration: Japan Registry of Clinical Trials jRCTs041210014; https://jrct.niph.go.jp/latest-detail/jRCTs041210014 International Registered Report Identifier (IRRID): DERR1-10.2196/59928
- 9 September 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e59928
Open AccessPrevention of Recurrent Spontaneous Preterm Delivery Using Probiotics (Clostridium butyricum, Enterococcus faecium, and Bacillus subtilis; PPP Trial): Protocol for a Prospective, Single-Arm, Nonblinded, Multicenter Trial
Background: The rate of recurrent spontaneous preterm delivery (sPTD) ranges between 27% and 34% and is 22.3% in Japan. Although it currently remains unclear whether probiotics prevent sPTD, retrospective studies recently reported a reduction in the rate of recurrent sPTD with the administration of probiotics including Clostridium spp., which induce regulatory T cells that play an important role in maintaining pregnancy. Objective: The objective of this trial is to evaluate the preventative effects of available oral probiotics, including Clostridium butyricum, on recurrent sPTD. Methods: This is a prospective, single-arm, nonblinded, multicenter trial in Japan. The sample size required for this trial is 345 pregnant women with a history of sPTD, considering a clinically significant reduction in the relative risk of 30% (risk ratio=0.7). The primary endpoint is the rate of recurrent sPTD at <37 weeks of gestation. The secondary endpoints are the rate of sPTD at <34 weeks of gestation, the rate of recurrent sPTD at <28 weeks of gestation, the ratio of intestinal Clostridium spp. (detected by next-generation sequencing), and bacterial vaginosis (using the Nugent score). Results: The trial procedures were approved by the Clinical Research Review Board of Toyama University Hospital (SCR2020008) on March 31, 2021. The trial was registered on the Japan Registry of Clinical Trial website on April 28, 2021. Recruitment began on May 1, 2021, and the trial is estimated to finish on March 31, 2025. Conclusions: The findings will clarify the rate of recurrent sPTD following probiotic administration including Clostridium butyricum. Outcomes from this trial will inform clinical practice and guide future randomized controlled trials. Trial Registration: Japan Registry of Clinical Trials jRCTs041210014; https://jrct.niph.go.jp/latest-detail/jRCTs041210014 International Registered Report Identifier (IRRID): DERR1-10.2196/59928
- Open Access
- 26 April 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Prevention of Recurrent Spontaneous Preterm Delivery Using Probiotics (Clostridium butyricum, Enterococcus faecium, and Bacillus subtilis; PPP Trial): Protocol for a Prospective, Single-Arm, Nonblinded, Multicenter Trial (Preprint)
BACKGROUND The rate of recurrent spontaneous preterm delivery (sPTD) ranges between 27% and 34% and is 22.3% in Japan. Although it currently remains unclear whether probiotics prevent sPTD, retrospective studies recently reported a reduction in the rate of recurrent sPTD with the administration of probiotics including Clostridium spp., which induce regulatory T cells that play an important role in maintaining pregnancy. OBJECTIVE The objective of this trial is to evaluate the preventative effects of available oral probiotics, including Clostridium butyricum, on recurrent sPTD. METHODS This is a prospective, single-arm, nonblinded, multicenter trial in Japan. The sample size required for this trial is 345 pregnant women with a history of sPTD, considering a clinically significant reduction in the relative risk of 30% (risk ratio=0.7). The primary endpoint is the rate of recurrent sPTD at <37 weeks of gestation. The secondary endpoints are the rate of sPTD at <34 weeks of gestation, the rate of recurrent sPTD at <28 weeks of gestation, the ratio of intestinal Clostridium spp. (detected by next-generation sequencing), and bacterial vaginosis (using the Nugent score). RESULTS The trial procedures were approved by the Clinical Research Review Board of Toyama University Hospital (SCR2020008) on March 31, 2021. The trial was registered on the Japan Registry of Clinical Trial website on April 28, 2021. Recruitment began on May 1, 2021, and the trial is estimated to finish on March 31, 2025. CONCLUSIONS The findings will clarify the rate of recurrent sPTD following probiotic administration including Clostridium butyricum. Outcomes from this trial will inform clinical practice and guide future randomized controlled trials. CLINICALTRIAL Japan Registry of Clinical Trials jRCTs041210014; https://jrct.niph.go.jp/latest-detail/jRCTs041210014 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/59928
- 26 April 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPrevention of Recurrent Spontaneous Preterm Delivery Using Probiotics (Clostridium butyricum, Enterococcus faecium, and Bacillus subtilis; PPP Trial): Protocol for a Prospective, Single-Arm, Nonblinded, Multicenter Trial (Preprint)
BACKGROUND The rate of recurrent spontaneous preterm delivery (sPTD) ranges between 27% and 34% and is 22.3% in Japan. Although it currently remains unclear whether probiotics prevent sPTD, retrospective studies recently reported a reduction in the rate of recurrent sPTD with the administration of probiotics including Clostridium spp., which induce regulatory T cells that play an important role in maintaining pregnancy. OBJECTIVE The objective of this trial is to evaluate the preventative effects of available oral probiotics, including Clostridium butyricum, on recurrent sPTD. METHODS This is a prospective, single-arm, nonblinded, multicenter trial in Japan. The sample size required for this trial is 345 pregnant women with a history of sPTD, considering a clinically significant reduction in the relative risk of 30% (risk ratio=0.7). The primary endpoint is the rate of recurrent sPTD at <37 weeks of gestation. The secondary endpoints are the rate of sPTD at <34 weeks of gestation, the rate of recurrent sPTD at <28 weeks of gestation, the ratio of intestinal Clostridium spp. (detected by next-generation sequencing), and bacterial vaginosis (using the Nugent score). RESULTS The trial procedures were approved by the Clinical Research Review Board of Toyama University Hospital (SCR2020008) on March 31, 2021. The trial was registered on the Japan Registry of Clinical Trial website on April 28, 2021. Recruitment began on May 1, 2021, and the trial is estimated to finish on March 31, 2025. CONCLUSIONS The findings will clarify the rate of recurrent sPTD following probiotic administration including Clostridium butyricum. Outcomes from this trial will inform clinical practice and guide future randomized controlled trials. CLINICALTRIAL Japan Registry of Clinical Trials jRCTs041210014; https://jrct.niph.go.jp/latest-detail/jRCTs041210014 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/59928
- Open Access
- 5 September 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (17) , e029268
Association Between Maternal Factors in Early Pregnancy and Congenital Heart Defects in Offspring: The Japan Environment and Children's Study
Background: Many prenatal factors are reported to be associated with congenital heart defects (CHD) in offspring. However, these associations have not been adequately examined using large‐scale birth cohorts. Methods and Results: We evaluated a data set of the Japan Environmental and Children's Study. The primary outcome was a diagnosis of CHD by age 2 years. We defined the following variables as exposures: maternal baseline characteristics, fertilization treatment, maternal history of diseases, socioeconomic status, maternal alcohol intake, smoking, tea consumption, maternal dietary intake, and maternal medications and supplements up to 12 weeks of gestation. We used multivariable logistic regression analysis to assess the associations between various exposures and CHD in offspring. A total of 91 664 singletons were included, among which 1264 (1.38%) had CHD. In multivariable analysis, vitamin A supplements (adjusted odds ratio [aOR], 5.78 [95% CI, 2.30–14.51]), maternal use of valproic acid (aOR, 4.86 [95% CI, 1.51–15.64]), maternal use of antihypertensive agents (aOR, 3.80 [95% CI, 1.74–8.29]), maternal age ≥40 years (aOR, 1.59 [95% CI, 1.14–2.20]), and high maternal hemoglobin concentration in the second trimester (aOR, 1.10 per g/dL [95% CI, 1.03–1.17]) were associated with CHD in offspring. Conclusions: Using a Japanese large‐scale birth cohort study, we found 6 maternal factors to be associated with CHD in offspring.
- 5 September 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (17) , e029268
Open AccessAssociation Between Maternal Factors in Early Pregnancy and Congenital Heart Defects in Offspring: The Japan Environment and Children's Study
Background: Many prenatal factors are reported to be associated with congenital heart defects (CHD) in offspring. However, these associations have not been adequately examined using large‐scale birth cohorts. Methods and Results: We evaluated a data set of the Japan Environmental and Children's Study. The primary outcome was a diagnosis of CHD by age 2 years. We defined the following variables as exposures: maternal baseline characteristics, fertilization treatment, maternal history of diseases, socioeconomic status, maternal alcohol intake, smoking, tea consumption, maternal dietary intake, and maternal medications and supplements up to 12 weeks of gestation. We used multivariable logistic regression analysis to assess the associations between various exposures and CHD in offspring. A total of 91 664 singletons were included, among which 1264 (1.38%) had CHD. In multivariable analysis, vitamin A supplements (adjusted odds ratio [aOR], 5.78 [95% CI, 2.30–14.51]), maternal use of valproic acid (aOR, 4.86 [95% CI, 1.51–15.64]), maternal use of antihypertensive agents (aOR, 3.80 [95% CI, 1.74–8.29]), maternal age ≥40 years (aOR, 1.59 [95% CI, 1.14–2.20]), and high maternal hemoglobin concentration in the second trimester (aOR, 1.10 per g/dL [95% CI, 1.03–1.17]) were associated with CHD in offspring. Conclusions: Using a Japanese large‐scale birth cohort study, we found 6 maternal factors to be associated with CHD in offspring.
- 4 April 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (4) , e14524
Perioperative risk factors for neurological impairment in infants with acute liver failure following liver transplantation
Background: Neurological impairment is not rare in infants with acute liver failure (ALF). This study aimed to investigate the perioperative risk factors for neurological impairment following liver transplantation (LT) in infantile ALF.Methods: Retrospective analysis was performed in infants who were younger than 1 year with ALF who subsequently underwent LT at our hospital between January 2005 and December 2016. Patients were considered to have neurological impairment if the Pediatric Cerebral Performance Category score was between 2 and 5 at the age of 6 years. A comparison between the groups of infants with and without neurological impairment was performed, and factors with p < .10 in the comparison were analyzed using univariate logistic regression analysis for neurological impairment.Results: Twenty‐six infants survived until 6 years of age, and 31% (8/26) of them had neurological impairment. Patients with neurological impairment were significantly younger in age at ALF onset, had significantly higher pre‐LT bilirubin and prothrombin time/international normalized ratio, and stayed significantly longer in the intensive care unit than those without neurological impairment. Total bilirubin (odds ratio (OR) = 1.12, 95% confidence interval (CI) 1.02–1.22, p = .012), indirect bilirubin (OR = 1.10, 95% CI 1.01–1.20, p = .025), direct bilirubin (OR = 1.22, 95% CI 1.01–1.47, p = .040), and age in month at ALF (OR = 0.76, 95% CI 0.58–0.999, p = .049) showed significant association with neurological impairment.Conclusions: High pre‐LT peak bilirubin value and younger age at ALF onset can be perioperative risk factors for neurological impairment after LT in infantile ALF.
- 4 April 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (4) , e14524
Perioperative risk factors for neurological impairment in infants with acute liver failure following liver transplantation
Background: Neurological impairment is not rare in infants with acute liver failure (ALF). This study aimed to investigate the perioperative risk factors for neurological impairment following liver transplantation (LT) in infantile ALF.Methods: Retrospective analysis was performed in infants who were younger than 1 year with ALF who subsequently underwent LT at our hospital between January 2005 and December 2016. Patients were considered to have neurological impairment if the Pediatric Cerebral Performance Category score was between 2 and 5 at the age of 6 years. A comparison between the groups of infants with and without neurological impairment was performed, and factors with p < .10 in the comparison were analyzed using univariate logistic regression analysis for neurological impairment.Results: Twenty‐six infants survived until 6 years of age, and 31% (8/26) of them had neurological impairment. Patients with neurological impairment were significantly younger in age at ALF onset, had significantly higher pre‐LT bilirubin and prothrombin time/international normalized ratio, and stayed significantly longer in the intensive care unit than those without neurological impairment. Total bilirubin (odds ratio (OR) = 1.12, 95% confidence interval (CI) 1.02–1.22, p = .012), indirect bilirubin (OR = 1.10, 95% CI 1.01–1.20, p = .025), direct bilirubin (OR = 1.22, 95% CI 1.01–1.47, p = .040), and age in month at ALF (OR = 0.76, 95% CI 0.58–0.999, p = .049) showed significant association with neurological impairment.Conclusions: High pre‐LT peak bilirubin value and younger age at ALF onset can be perioperative risk factors for neurological impairment after LT in infantile ALF.
- Open Access
How a Family History of Allergic Diseases Influences Food Allergy in Children: The Japan Environment and Children’s Study
The influence of family allergic history on food allergy in offspring in Japan is unknown. We analyzed data from a nationwide birth cohort study using logistic regression models to examine the associations of maternal, paternal, and both parental histories of allergic diseases (food allergy, atopic dermatitis, asthma, and rhinitis) with their child’s food allergy at 1.5 and 3 years of age. This analysis included 69,379 singleton full-term mothers and 37,179 fathers and their children. All parental histories of allergic diseases showed significant positive associations with their child’s food allergy. When both parents had a history of allergic diseases, the adjusted odds ratio (aOR) tended to be higher than when either parent had allergic diseases (p for trend < 0.0001). The highest aOR was detected when both parents had food allergy (2.60; 95% confidential interval, 1.58–4.27), and the aOR was 1.71 when either parent had food allergy (95% confidential interval, 1.54–1.91). The aORs were attenuated but still had significant positive associations after adjusting for the child’s atopic dermatitis, a risk factor for allergy development. In conclusion, all parental allergic diseases were significantly positively associated with their child’s food allergy. The effect of family history showed a stepwise increase in risk from either parent to both parents, and the highest risk of allergic disease was a parental history of food allergy.
Open AccessHow a Family History of Allergic Diseases Influences Food Allergy in Children: The Japan Environment and Children’s Study
The influence of family allergic history on food allergy in offspring in Japan is unknown. We analyzed data from a nationwide birth cohort study using logistic regression models to examine the associations of maternal, paternal, and both parental histories of allergic diseases (food allergy, atopic dermatitis, asthma, and rhinitis) with their child’s food allergy at 1.5 and 3 years of age. This analysis included 69,379 singleton full-term mothers and 37,179 fathers and their children. All parental histories of allergic diseases showed significant positive associations with their child’s food allergy. When both parents had a history of allergic diseases, the adjusted odds ratio (aOR) tended to be higher than when either parent had allergic diseases (p for trend < 0.0001). The highest aOR was detected when both parents had food allergy (2.60; 95% confidential interval, 1.58–4.27), and the aOR was 1.71 when either parent had food allergy (95% confidential interval, 1.54–1.91). The aORs were attenuated but still had significant positive associations after adjusting for the child’s atopic dermatitis, a risk factor for allergy development. In conclusion, all parental allergic diseases were significantly positively associated with their child’s food allergy. The effect of family history showed a stepwise increase in risk from either parent to both parents, and the highest risk of allergic disease was a parental history of food allergy.
- 30 March 2022
- Published by Wiley in American Journal of Hematology
- Vol. 97 (6) , 780-790
Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein–Barr virus infection patients in Japan
The effects of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) on systemic chronic active Epstein–Barr virus infection (sCAEBV) are yet to be analyzed in a large number of patients. Using the Japanese registry database, Transplant Registry Unification Management Program, we investigated the outcomes of 102 sCAEBV patients who underwent allo‐HSCT. The median age at HSCT was 21 years, and the three‐year overall survival (3‐year OS) rate was 72.5%. Of the 90 patients whose viral load after allo‐HSCT was evaluated, 56 (62.2%) achieved a virological complete response, defined by the complete resolution of disease activity with a significant decrease in EBV‐DNA in peripheral blood. The multivariate Cox proportional hazard model indicated that advanced age, in adolescents and young adults (AYA) (age, 15–39) and adults (age, ≥40 years) was a risk factor of poor OS. The hazard ratios (HRs) of the AYA and adult groups were 10.87 (95% confidence interval [CI]: 1.98–59.56, p = .006) and 15.93 (95% CI: 2.45–103.8, p = .004), respectively. Disease activity (HR 5.74), elevated soluble IL‐2 receptor (sIL‐2R) (≥ median, 691 U/mL) at HSCT (HR 6.93), and conditioning without radiotherapy (HR 3.53) were also independently associated with poor survival. Notably, 79% of radiotherapy doses were less than 6 Gy. Regardless of the presence of hemophagocytic lymphohistiocytosis, the group with a high sIL‐2R level (≥2000 U/mL) showed a poorer prognosis. Although allo‐HSCT is the only curative therapy for sCAEBV, treatment strategies need to be improved for high‐risk patients, especially those with high levels of sIL‐2R.
- 30 March 2022
- Published by Wiley in American Journal of Hematology
- Vol. 97 (6) , 780-790
Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein–Barr virus infection patients in Japan
The effects of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) on systemic chronic active Epstein–Barr virus infection (sCAEBV) are yet to be analyzed in a large number of patients. Using the Japanese registry database, Transplant Registry Unification Management Program, we investigated the outcomes of 102 sCAEBV patients who underwent allo‐HSCT. The median age at HSCT was 21 years, and the three‐year overall survival (3‐year OS) rate was 72.5%. Of the 90 patients whose viral load after allo‐HSCT was evaluated, 56 (62.2%) achieved a virological complete response, defined by the complete resolution of disease activity with a significant decrease in EBV‐DNA in peripheral blood. The multivariate Cox proportional hazard model indicated that advanced age, in adolescents and young adults (AYA) (age, 15–39) and adults (age, ≥40 years) was a risk factor of poor OS. The hazard ratios (HRs) of the AYA and adult groups were 10.87 (95% confidence interval [CI]: 1.98–59.56, p = .006) and 15.93 (95% CI: 2.45–103.8, p = .004), respectively. Disease activity (HR 5.74), elevated soluble IL‐2 receptor (sIL‐2R) (≥ median, 691 U/mL) at HSCT (HR 6.93), and conditioning without radiotherapy (HR 3.53) were also independently associated with poor survival. Notably, 79% of radiotherapy doses were less than 6 Gy. Regardless of the presence of hemophagocytic lymphohistiocytosis, the group with a high sIL‐2R level (≥2000 U/mL) showed a poorer prognosis. Although allo‐HSCT is the only curative therapy for sCAEBV, treatment strategies need to be improved for high‐risk patients, especially those with high levels of sIL‐2R.
- Open Access
- 20 January 2022
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 26, 100892
A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease with coronary artery aneurysm: Study protocol of a multicenter, single-arm, open-label trial
- 20 January 2022
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 26, 100892
Open AccessA phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease with coronary artery aneurysm: Study protocol of a multicenter, single-arm, open-label trial